APASL 2014: HCV Abstract and Poster Presentation Coverage by Jules Levin (NATAP)

(APASL) 24th Conference of the Asian Pacific
Association for the Study of the Liver
12-15 March, 2014
Brisbane, Australia

Reported by Jules Levin

(All links open into new windows)

• APASL: High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study - (03/19/14)
• APASL: Sofosbuvir Plus Ribavirin For HCV Genotype 1-3 Infection in HIV Co-infected Patients (PHOTON-1) - (03/19/14)
• APASL: Once-Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin Resulted in 97% Sustained Virologic Response in Patients With HCV Genotype 1, Including Patients With Cirrhosis: The LONESTAR Trial - (03/19/14)
• APASL: A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study - (03/19/14)
• APASL: Simeprevir (TMC435) with peginterferon-α/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in patients with genotype 1b HCV in the QUEST-1 and -2 Phase III trials - (03/19/14)
• APASL: Interferon- and Ribavirin-Free Regimen of ABT-450/r and ABT-267 in Treatment-Experienced Japanese Patients Infected With HCV Genotype 1b or Genotype 2 - (03/17/14)
• APASL: Pharmacokinetics of ABT-450/r and ABT-267 in Treatment-Experienced HCV Subgenotype 1b- and Genotype 2-Infected Japanese Subjects - (03/17/14)
• APASL: Concordance of SVR12 With SVR4 and SVR24 in Patients With Chronic HCV Genotype 1b Treated With the Interferon- and Ribavirin-free ABT-450/r and ABT-267 Regimen - (03/17/14)
• APASL: Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin in Patients With Inherited Bleeding Disorders and HCV Infection - (03/17/14)
• APASL: High Sustained Response Rates With Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients With HCV Genotype 2 or 3 Infection: The VALENCE Trial - (03/17/14)
• APASL: Sofosbuvir in Combination With Pegylated Interferon-alfa and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment-Experienced Patients With and Without Compensated Cirrhosis: Results From the LONESTAR-2 Study - (03/17/14)
• APASL: Once Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination With or Without Ribavirin: Data From the ELECTRON Trials - (03/17/14)
• APASL: Cross-Study Analysis of the Efficacy of the All-Oral Combination of Daclatasvir (DCV) and Asunaprevir (ASV) in Patients with HCV Genotype 1b Infection - (03/17/14)
• APASL: On-Treatment Predictors of Response to Daclatasvir (DCV) in Combination With Asunaprevir (ASV) in Japanese Patients With Genotype 1b Infection - (03/17/14)
• APASL: Investigating treatment strategies to optimise clinical outcomes associated with emerging therapies for HCV - (03/17/14)
• APASL: Efficacy and Safety of Daclatasvir (DCV) in Combination With Asunaprevir (ASV) in Cirrhotic and Non-Cirrhotic Patients With Hepatitis C Virus (HCV) Genotype 1b Infection - (03/17/14)
• APASL: Effect of Demographic and Baseline Disease Characteristics on the Efficacy and Safety of Daclatasvir in Combination With Asunaprevir in Japanese Patients With HCV Genotype 1b Infection - (03/17/14)

Source NATAP